Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis

Company Overview

Navidea Biopharmaceuticals, Inc. is a biotechnology company focused on precision medicine, with an emphasis on radiopharmaceuticals and agents designed to target immune cells and lymphatic tissue. Its research is based primarily on the Manocept platform, which is intended to support diagnostic imaging and potential therapeutic applications in diseases involving the immune system.

The company’s best-known product is Lymphoseek (technetium Tc 99m tilmanocept injection), a radiopharmaceutical used to help identify and map lymph nodes during procedures involving certain cancers, including breast cancer and melanoma. Lymphoseek has received regulatory approval in the United States and Europe for specified lymphatic mapping applications. Navidea has also pursued additional diagnostic and therapeutic uses of the Manocept platform, including investigational applications in inflammatory and immune-mediated diseases.

Navidea was formerly known as Neoprobe and adopted its current name in 2012 as it shifted its focus toward the Manocept technology. The company has worked with commercial and development partners to support the distribution and further development of its products in the United States and international markets. Its pipeline beyond Lymphoseek remains focused on investigational programs, and product availability and development status may vary by geography.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 7,146 shs
• Market Capitalization: $10 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:NAVB
• CIK: 810509
• Web: www.navidea.com
• Phone: 614-793-7500
• Fax: 614-793-7522
• Employees: 10
• Year Founded: 1983

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $8.13 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 100,080,000
• Free Float: 56,367,000
• Market Cap: $10 thousand
• Optionable: No Data
• Beta: 1.76